Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy through TCR gene transfer.

H W Kessels1, M C Wolkers, M D van den Boom

  • 1Division of Immunology, Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

Nature Immunology
|September 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Immuno-oncology technology·2025
Same author

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

BMC cancer·2022
Same author

Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.

Immuno-oncology technology·2022
Same author

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

Immuno-oncology technology·2022
Same author

[Oral care for patients in the palliative stage of life - do you care?]

Nederlands tijdschrift voor tandheelkunde·2020

Genetic transfer of T cell receptors (TCRs) redirected T cells to target viruses and tumors. This TCR gene transfer strategy successfully induced antigen-specific immunity without significant autoimmune issues in a mouse model.

Area of Science:

  • Immunology
  • Molecular Biology
  • Gene Therapy

Background:

  • T cell receptor (TCR) alpha and beta chains determine antigen specificity.
  • TCR gene transfer offers a potential method to engineer T cell specificity for therapeutic applications.

Purpose of the Study:

  • To investigate the feasibility of genetically introducing a virus-specific TCR into peripheral T cells.
  • To evaluate the efficacy and safety of TCR gene transfer for inducing virus- or tumor-specific immunity.

Main Methods:

  • Genetic introduction of a virus-specific TCR into peripheral T cells in a mouse model.
  • Assessment of T cell expansion, homing to effector sites, and autoimmune pathology post-viral infection.
  • Evaluation of tumor rejection in vivo following TCR gene transfer.

Related Experiment Videos

Main Results:

  • Redirected T cells expanded upon viral infection and effectively homed to effector sites.
  • TCR gene transfer did not result in significant autoimmune pathology.
  • Small numbers of TCR-transduced T cells facilitated the rejection of antigen-expressing tumors.

Conclusions:

  • TCR gene transfer is a viable strategy for redirecting T cells.
  • This approach enables the rapid induction of virus- or tumor-specific immunity.
  • The method shows promise for therapeutic applications in infectious diseases and oncology.